This product is specifically developed for the large-scale production of AAV in suspension systems. It is an optimized and modified linear polyethylenimine (Polyethylenimine Linear, PEI). The product is synthesized purely through chemical processes, free from animal-derived components, and has low cytotoxicity. It also offers broad applicability across various AAV serotypes. With high DNA loading capacity, a low transfection complex ratio, and high complex stability, this product facilitates large-scale AAV production. The product is manufactured in accordance with GMP requirements and is provided in the form of a sterile liquid. Features Significant Increase in Virus Titer: The product achieves a substantial increase in virus yield, with approximately a 2-fold increase in virus titer for multiple serotypes, including AAV2, AAV5, AAV8, and AAV9. Reduced Usage Cost: By reducing the amount of transfection reagent by 50% while maintaining high yield, the product effectively lowers production costs. Applications Production of AAV Viral Vectors Specifications Form liquid Properties Polyethylenimine Linear (PEI) Virus Type AAV Components Components No. Name 40824ES10 40824ES60 40824ES80 40824 Hieff Trans™ PEI AAV Transfection Reagent-GMP 10 mL 100 mL 1 L Shipping and Storage Hieff Trans™ PEI AAV Transfection Reagent-GMP products should be stored at 2-8℃ for 2 year. Figures Figure1. Hieff Trans™ PEI AAV showing ultra trans-effciency compared with top PEIs. AAV2, AAV5, AAV8, and AAV9 were produced in suspension 293F cells, with a DNA dosage of 1 µg per million cells. The virus was harvested 72 hours post-transfection, and the viral supernatant was analyzed. Figure2. Hieff Trans™ PEI showing low inputs. AAV9 was produced in suspension 293F cells with different input of Ultra-PEI (Left, Plasmids input: 0.5 μg) or Plasmids (Right, Ultra-PEI input 0.6 μL) dosages per million cells. The virus was harvested 72 hours post-transfection. Documents: Safety Data Sheet 40824_MSDS_HB250121 Manuals 40824_Manual_Ver.EN20250121